The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Distinct granular cytoplasmic and in rare cases also nuclear positivity was observed in several cases of malignant glioma whereas several cases of renal cancers and thyroid cancers displayed moderate cytoplasmic positivity. Remaining malignant cells were weakly stained or generally negative.
Malignant cells generally showed weak cytoplasmic positivity or were negative. Hepatocellular carcinomas, the majority of renal cancers along with several prostate and testicular cancers were moderately stained.
Malignant glioma, prostate, endometrial, renal and liver cancer generally displayed moderate cytoplasmic staining. Remaining malignant cells were mainly negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
